Condition: Neuromyelitis Optica Spectrum Disorder · Sponsor: Amgen
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin \[Ig\]G).
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| UCSD Altman Clinical and Translational Research Institute Building | La Jolla, California, United States | Recruiting |
| Loma Linda University Children's Hospital - PIN | Loma Linda, California, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan | Parque Patricios, Ciudad Autónoma de BuenosAires, Argentina | Recruiting |
| Hospital Santa Izabel-Rua Floriano Peixoto 300 | Salvador, Estado de Bahia, Brazil | Recruiting |
| Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS) | Porto Alegre/RS, Brazil | Recruiting |
| CPQuali Pesquisa Clínica Sao Paulo | São Paulo, Brazil | Recruiting |
| Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo | São Paulo, Brazil | Recruiting |
| Hospital For Sick Children | Toronto, Ontario, Canada | Recruiting |
| Centre Hospitalier Universitaire de Bicêtre | Le Kremlin-Bicêtre, Val-de-Marne, France | Recruiting |
| Erasmus MC Sophia Children's Hospital-Wytemaweg 80 | Rotterdam, South Holland, Netherlands | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05549258